Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGC Canopy Growth	$1.44 +13.4%	$1.22	$0.77 ▼ $6.27	$345.38M	0.67	10.24 million shs	34.69 million shs
FHTX Foghorn Therapeutics	$5.25 -5.6%	$5.26	$2.94 ▼ $10.25	$296.78M	3.05	128,712 shs	76,306 shs
JMAC Maxpro Capital Acquisition	$6.04 -0.1%	$6.04	$7.50 ▼ $19.22	$81.17M	0.01	74,040 shs	13,089 shs
RNAC Cartesian Therapeutics	$11.25 +0.2%	$11.67	$8.46 ▼ $26.50	$292.52M	0.44	81,280 shs	33,063 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGC Canopy Growth	0.00%	-2.31%	+11.40%	-30.60%	-79.55%
FHTX Foghorn Therapeutics	0.00%	+11.65%	-10.18%	+34.30%	-30.59%
JMAC Maxpro Capital Acquisition	0.00%	+6.61%	-1.71%	-14.62%	+4,280.14%
RNAC Cartesian Therapeutics	0.00%	-0.88%	-15.75%	+22.60%	-18.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGC Canopy Growth	0.7382 of 5 stars	0.0	2.0	0.0	0.0	3.3	0.8	1.3
FHTX Foghorn Therapeutics	2.2591 of 5 stars	3.6	3.0	0.0	0.0	0.6	1.7	0.6
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	2.5821 of 5 stars	3.4	2.0	0.0	0.0	2.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGC Canopy Growth	1.33	Sell	N/A	N/A
FHTX Foghorn Therapeutics	3.17	Buy	$10.67	103.17% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$40.00	255.56% Upside

Current Analyst Ratings Breakdown

Latest JMAC, CGC, RNAC, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CGC Canopy Growth	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGC Canopy Growth	$225.65M	1.53	N/A	N/A	$1.90 per share	0.76
FHTX Foghorn Therapeutics	$22.60M	13.13	N/A	N/A	($0.82) per share	-6.40
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	$1.03M	285.11	N/A	N/A	($0.27) per share	-41.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGC Canopy Growth	-$429.86M	-$3.03	N/A	N/A	N/A	-155.76%	-89.93%	-44.24%	N/A
FHTX Foghorn Therapeutics	-$86.62M	-$1.19	N/A	N/A	N/A	-311.90%	N/A	-28.00%	11/3/2025 (Estimated)
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-6.36%	11/6/2025 (Estimated)

Latest JMAC, CGC, RNAC, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q1 2026	CGC Canopy Growth	-$0.15	-$0.14	+$0.01	-$0.16	$64.98 million	$52.98 million
8/7/2025	Q2 2025	RNAC Cartesian Therapeutics	-$0.76	$0.50	+$1.26	$0.50	$0.77 million	$0.30 million
8/5/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	$7.62 million	$7.56 million
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGC Canopy Growth	0.59	3.07	2.12
FHTX Foghorn Therapeutics	N/A	2.62	2.62
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	13.33	13.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGC Canopy Growth	3.33%
FHTX Foghorn Therapeutics	61.55%
JMAC Maxpro Capital Acquisition	73.18%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
CGC Canopy Growth	0.16%
FHTX Foghorn Therapeutics	7.58%
JMAC Maxpro Capital Acquisition	19.27%
RNAC Cartesian Therapeutics	60.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGC Canopy Growth	3,150	239.85 million	239.47 million	Optionable
FHTX Foghorn Therapeutics	120	56.53 million	52.25 million	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
RNAC Cartesian Therapeutics	64	26.00 million	10.32 million	Optionable

JMAC, CGC, RNAC, and FHTX Headlines

Recent News About These Companies

Erste Asset Management GmbH Buys 86,445 Shares of Cartesian Therapeutics, Inc. $RNAC

August 24 at 5:36 AM | marketbeat.com

Mizuho Securities Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)

August 15, 2025 | theglobeandmail.com

BTIG Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)

August 14, 2025 | theglobeandmail.com

Oppenheimer Sticks to Their Hold Rating for Cartesian Therapeutics (RNAC)

August 14, 2025 | theglobeandmail.com

Cartesian (RNAC) Q2 Revenue Drops 99%

August 9, 2025 | theglobeandmail.com

Cartesian Therapeutics Reports Positive Q2 2025 Earnings

August 8, 2025 | tipranks.com

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | taiwannews.com.twT

Cartesian Therapeutics (RNAC) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 4, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?

July 24, 2025 | zacks.com

Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation

July 9, 2025 | msn.com

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

June 21, 2025 | finance.yahoo.com

Cartesian Therapeutics holds annual stockholders meeting

June 17, 2025 | investing.com

Cartesian Therapeutics Announces New Employment Inducement Grants

June 3, 2025 | globenewswire.com

BTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 2, 2025 | theglobeandmail.com

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 30, 2025 | globenewswire.com

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 13, 2025 | manilatimes.netM

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 11, 2025 | finance.yahoo.com

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC, CGC, RNAC, and FHTX Company Descriptions

Canopy Growth NASDAQ:CGC

$1.44 +0.17 (+13.39%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.02 (+1.04%)

As of 05:35 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Foghorn Therapeutics NASDAQ:FHTX

$5.25 -0.31 (-5.58%)

Closing price 04:00 PM Eastern

Extended Trading

$5.24 -0.01 (-0.19%)

As of 04:10 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Maxpro Capital Acquisition NASDAQ:JMAC

$6.04 -0.01 (-0.09%)

As of 08/22/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Cartesian Therapeutics NASDAQ:RNAC

$11.25 +0.02 (+0.18%)

Closing price 04:00 PM Eastern

Extended Trading

$11.22 -0.04 (-0.31%)

As of 04:10 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time